TY - JOUR AU - Yamada, Shutaro AU - Imura, Yoshinori AU - Nakai, Takaaki AU - Nakai, Sho AU - Yasuda, Naohiro AU - Kaneko, Keiko AU - Outani, Hidetatsu AU - Takenaka, Satoshi AU - Hamada, Kenichiro AU - Myoui, Akira AU - Araki, Nobuhito AU - Ueda, Takafumi AU - Itoh, Kazuyuki AU - Yoshikawa, Hideki AU - Naka, Norifumi PY - 2017 DA - 2017/05/16 TI - Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma JO - BMC Cancer SP - 334 VL - 17 IS - 1 AB - The prognosis of synovial sarcoma (SS), an aggressive soft tissue sarcoma, remains poor. We previously reported that c-MET or platelet-derived growth factor receptor α (PDGFRα) signalling pathway is related to SS progression based upon the findings of phospho-receptor tyrosine kinase (RTK) arrays. TAS-115 is a novel c-MET/ vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitor that has been shown to inhibit multiple RTKs. Here we aimed to investigate the therapeutic potential of TAS-115 against SS. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-017-3324-3 DO - 10.1186/s12885-017-3324-3 ID - Yamada2017 ER -